论文部分内容阅读
目的:评价凯时注射液(kaishiinjection)洽疗慢性肝病黄疸的疗效。方法:将58例慢性肝病黄疸患者随机分为凯时注射液组和对照组;凯时注射液组在对照组基础(葡萄糖、肌苷、维生素C及肝泰乐等)上加用凯时注射液10μg·d-1,静脉注射,疗程4周;测定治疗前后总胆红素(TB)、直接胆红素(DB)、丙氨酸转氨酶(ALT)、门冬氨酸转氨酶(AST)、碱性磷酸酶(AKP)、白蛋白(ALB)及球蛋白(GLB)等含最的变化;并观察症状和体征变化及不良反应。结果:在治疗4周后,凯时注射液组和对照组显效率分别为30.00%(9/30)和14.29%(4/28),有效率分别为53.33%(16/30)和42.86%(12/28),无效率分别为16.67%(5/30)和42.86%(12/28),凯时注射液组总有效率83.33%(25/30)明显优于对照组57.14%(16/28)(P<0.05);凯时注射液能明显降低慢性肝病黄疸患者的TB、DB、AKP、ALT和AST(P<0.05),对ALB和GLB则无明显影响(P<0.05);两组均无明显副作用。结论:凯时注射液能有效治疗慢性肝病的黄疸,且副作用少。
Objective: To evaluate the efficacy of kaishi injection in treating chronic liver disease jaundice. Methods: 58 patients with chronic liver disease jaundice were randomly divided into Kai Shi injection group and control group; Kai Shi injection group in the control group (glucose, inosine, vitamin C and liver Tailor, etc.) plus Kay injection (TB), direct bilirubin (DB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride Alkaline phosphatase (AKP), albumin (ALB) and globulin (GLB) with the most changes; and observe the changes in symptoms and signs and adverse reactions. Results: After 4 weeks of treatment, the effective rates were 30.00% (9/30) and 14.29% (4/28) in Kaye injection group and control group respectively, and the effective rates were 53.33% (16/30) and 42.86% (12/28), the inefficiencies were 16.67% (5/30) and 42.86% (12/28), respectively. The total effective rate was 83.33% (25/30) in the Kai Shi injection group significantly higher than that in the control group 57.14% (16 (P <0.05), but no significant effect on ALB and GLB (P <0.05). Conclusions: When administered with Kai Shi injection, TB, DB, AKP, ALT and AST in patients with chronic hepatic jaundice were significantly decreased No obvious side effects in both groups. Conclusions: Kay hours injection can effectively treat jaundice of chronic liver disease with few side effects.